Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
CONMED Corporation is a medical devices business based in the US. CONMED Corporation shares (CNMD) are listed on the NYSE and all prices are listed in US Dollars. CONMED Corporation employs 3,800 staff and has a trailing 12-month revenue of around $1.1 billion.
Finder Award
SoFi Invest
Robinhood
tastyworks
| Latest market close | $95.76 |
|---|---|
| 52-week range | $70.94 - $154.53 |
| 50-day moving average | $88.72 |
| 200-day moving average | $97.98 |
| Wall St. target price | $100.50 |
| PE ratio | 46.5048 |
| Dividend yield | $0.8 (0.83%) |
| Earnings per share (TTM) | $2.10 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $95.76 from 2023-01-31
| 1 week (2023-01-25) | 0.03% |
|---|---|
| 1 month (2022-12-30) | 8.03% |
| 3 months (2022-11-01) | 21.12% |
| 6 months (2022-08-01) | -1.86% |
| 1 year (2022-01-28) | -29.13% |
|---|---|
| 2 years (2021-02-01) | -14.52% |
| 3 years (2020-01-31) | 101.68 |
| 5 years (2018-02-01) | 51.16% |
Valuing CONMED Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CONMED Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
CONMED Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 47x. In other words, CONMED Corporation shares trade at around 47x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
CONMED Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.29. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into CONMED Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
CONMED Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $184.3 million.
The EBITDA is a measure of a CONMED Corporation's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.1 billion |
|---|---|
| Operating margin TTM | 11.07% |
| Gross profit TTM | $568 million |
| Return on assets TTM | 3.66% |
| Return on equity TTM | -11.24% |
| Profit margin | -7.74% |
| Book value | $23.50 |
| Market capitalisation | $3 billion |
TTM: trailing 12 months
Dividend payout ratio: 24.24% of net profits
Recently CONMED Corporation has paid out, on average, around 24.24% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.83% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), CONMED Corporation shareholders could enjoy a 0.83% return on their shares, in the form of dividend payments. In CONMED Corporation's case, that would currently equate to about $0.8 per share.
While CONMED Corporation's payout ratio might seem low, this can signify that CONMED Corporation is investing more in its future growth.
CONMED Corporation's most recent dividend payout was on 4 January 2023. The latest dividend was paid out to all shareholders who bought their shares by 14 December 2022 (the "ex-dividend date").
CONMED Corporation's shares were split on a 3:2 basis on 9 September 2001. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your CONMED Corporation shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for CONMED Corporation shares which in turn could have impacted CONMED Corporation's share price.
Over the last 12 months, CONMED Corporation's shares have ranged in value from as little as $70.9373 up to $154.5264. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while CONMED Corporation's is 1.339. This would suggest that CONMED Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida. .
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.